{ "context": [ [ "Insulin detemir", [ "Insulin detemir is a long-acting human insulin analogue for maintaining the basal level of insulin.", " Novo Nordisk markets it under the trade name Levemir.", " It is an insulin analogue in which a fatty acid (myristic acid) is bound to the lysine amino acid at position B29.", " It is quickly absorbed after which it binds to albumin in the blood through its fatty acid at position B29.", " It then slowly dissociates from this complex." ] ], [ "Insulin pen", [ "An insulin pen is used to inject insulin for the treatment of diabetes.", " Insulin is a hormone produced by the pancreas.", " It is composed of an insulin cartridge (integrated or bought separately) and a dial to measure the dose, and is used with disposable pen needles to deliver the dose.", " It was introduced and marketed as NovoPen by the Danish company Novo Nordisk in 1985." ] ], [ "Insulin aspart", [ "Insulin aspart is a fast-acting insulin analog marketed by Novo Nordisk as NovoLog/NovoRapid.", " It is a manufactured form of human insulin; where a single amino acid has been exchanged.", " This change helps the fast-acting insulin analog be absorbed quickly into the bloodstream.", " As a result, it starts working in minutes, which allows one to take insulin and eat right away.", " Fast-acting insulin analogs are considered to act similarly to the way insulin is released in people without diabetes mellitus." ] ], [ "Novo Nordisk", [ "Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsv√¶rd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries.", " Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (75%) of its voting shares." ] ], [ "Insulin glulisine", [ "Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.", " It was developed by Sanofi-Aventis and is sold under the trade name Apidra.", " When injected subcutaneously, it appears in the blood earlier than human insulin.", " When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.", " Intravenous